NCT05472012

Brief Summary

This study is designed to validate the performance of Masimo INVSENSOR00057 in detecting atrial fibrillation. The noninvasive ECG measurements will be compared to results obtained from an FDA-cleared ECG monitor.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
139

participants targeted

Target at P50-P75 for not_applicable atrial-fibrillation

Timeline
Completed

Started Jul 2022

Shorter than P25 for not_applicable atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 25, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

July 25, 2022

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 16, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 16, 2023

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

May 22, 2025

Completed
Last Updated

May 22, 2025

Status Verified

May 1, 2025

Enrollment Period

1.4 years

First QC Date

July 21, 2022

Results QC Date

May 6, 2025

Last Update Submit

May 6, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Sensitivity of INVSENSOR00057 Atrial Fibrillation (Afib) Detection Function

    Afib detection accuracy will be determined by analyzing the sensitivity of INVSENSOR00057 Afib detection function when compared to data collected using a FDA-cleared ECG monitor.

    1-5 hours

  • Specificity of INVSENSOR00057 Atrial Fibrillation (Afib) Detection Function

    Afib detection accuracy will be determined by analyzing the specificity of INVSENSOR00057 Afib detection function when compared to data collected using a FDA-cleared ECG monitor.

    1-5 hours

Study Arms (1)

INVSENSOR00057

EXPERIMENTAL

All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00057 device.

Device: INVSENSOR00057

Interventions

Noninvasive wearable health monitoring device

INVSENSOR00057

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is 18 years of age or older.
  • Subject is confirmed to have active atrial fibrillation at the time of enrollment.

You may not qualify if:

  • Subject is confirmed to have concurrent active arrhythmias (e.g., PVCs, bradycardia, etc.) at the time of enrollment.
  • Subject is allergic to adhesives or ECG gel.
  • Subject whose skin is not intact in or at the vicinity of the device placement site.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Site 1

Jackson, Tennessee, 38301, United States

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Chelsea Frank
Organization
Masimo

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2022

First Posted

July 25, 2022

Study Start

July 25, 2022

Primary Completion

December 16, 2023

Study Completion

December 16, 2023

Last Updated

May 22, 2025

Results First Posted

May 22, 2025

Record last verified: 2025-05

Locations